<DOC>
	<DOCNO>NCT02170662</DOCNO>
	<brief_summary>The purpose study determine effect bimatoprost solution scalp hair growth . Bimatoprost 0.03 % ophthalmic solution currently approve FDA treatment glaucoma ( Lumigan™ ) thicken thin eyelash ( Latisse™ ) . Bimatoprost 0.03 % approve treatment scalp hair loss use study consider investigational mean still test research study . Thirty-three subject consent screen , 9 enter 9 complete study .</brief_summary>
	<brief_title>Topical Bimatoprost Effect Androgen Dependent Hair Follicles</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>1 . HamiltonNorwood pattern baldness IIIV , IV , V , VA. 2 . Subject 's hair color must adequate contrast scalp color allow hair count macrophotography . 3 . Good health normal blood test hematological , renal , liver function . 4 . Able return Duke study visit . 1 . ECOG &gt; 1 . 2 . Used topical oral minoxidil past 6 month , oral finasteride past 12 month oral dutasteride past 24 month . 3 . Taken warfarin , heparin , retinoid great 2 week past 6 month past month . 4 . Taken chemotherapy past 2 year . 5 . Used overthecounter ( OTC ) preparation purport help hair growth past four month . 6 . Used prostaglandin type past currently . 7 . Any history alopecia areata , cicatricial alopecia , radiation head , hair transplant , scalp reduction . 8 . Any skin abnormality target area would effect hair growth . 9 . Any history glaucoma elevate intraocular pressure ( IOP ) . 10 . Any cancer nonmelanoma skin cancer ( NMSC ) past 2 year must remission .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>male pattern hair loss</keyword>
	<keyword>androgenetic alopecia</keyword>
	<keyword>bimatoprost</keyword>
</DOC>